Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present BeyondSpring Inc. (NASDAQ: BYSI).

Full DD Report for BYSI

You must become a subscriber to view this report.


Recent News from (NASDAQ: BYSI)

BeyondSpring Strengthens Intellectual Property Portfolio with Newly Granted U.S. Patent for Plinabulin
NEW YORK, Sept. 19, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, announced today that the U.S. Patent and Trademark Office (USPTO) has granted the Company a new pat...
Source: GlobeNewswire
Date: September, 19 2018 07:00
BeyondSpring's Lead Asset, Plinabulin, Shows Superior Efficacy Compared to Neulasta for Prevention of Thrombocytopenia Induced by Docetaxel in Phase 2 Trial
Data Provide Further Support for Plinabulin’s Superior Product Profile Clinical Data Will be Presented at 2018 IASLC 19th World Conference on Lung Cancer NEW YORK , Sept. 06, 2018 (GLOBE NEWSWIRE) --   BeyondSpring Inc . (NASDAQ:BYSI), a global, clinical-stage biophar...
Source: GlobeNewswire
Date: September, 06 2018 07:00
BeyondSpring to Present at the H.C. Wainwright 20th Annual Global Investment Conference
NEW YORK, Sept. 04, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced that Edward Liu, Chief Financial Officer, will present at the H.C. Wainwright ...
Source: GlobeNewswire
Date: September, 04 2018 07:00
BeyondSpring to Present Clinical Trial Data on Lead Asset, Plinabulin, at IASLC World Conference on Lung Cancer
NEW YORK, Aug. 15, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc . (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, announced today that the Company will present clinical data on its lead asset, Plinabulin, during a po...
Source: GlobeNewswire
Date: August, 15 2018 09:05
BeyondSpring Appoints Richard J. Daly as Chief Operating Officer to Lead the Transition to Commercialization
NEW YORK, Aug. 01, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc . (NASDAQ:BYSI) (“BeyondSpring” or the “Company”), a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, announced today the appointment of Richa...
Source: GlobeNewswire
Date: August, 01 2018 07:00
Playing The Expectations Game In Biotech
Investing in biotech stocks is not for the faint of heart. When positioned in the right biotech stocks, investors can be rewarded with explosive revenue growth and booming profitability from such companies, which generally means that the stock is delivering massive gains. On the other hand, th...
Source: SeekingAlpha
Date: July, 17 2018 21:11
Blog Exposure - Seattle Genetics Announces First Patient Dosage in Phase-2 innovaTV 207 Trial for Multiple Solid Tumors
Stock Monitor: BeyondSpring Post Earnings Reporting LONDON, UK / ACCESSWIRE / July 16, 2018 / If you want access to our free research report on Seattle Genetics, Inc. (NASDAQ: SGEN ), all you need to do is sign up now by clicking the following link www.active-investors.com/registratio...
Source: ACCESSWIRE IA
Date: July, 16 2018 07:40
BeyondSpring's Principal Investigator in China for Chemotherapy-Induced Neutropenia Delivered Keynote Presentation at 12th Annual Chinese Symposium on Medical Oncology and 7th Annual Meeting of the Chinese Association for Clinical Oncologists
NEW YORK, June 25, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, announced today that Dr. Yuankai Shi presented positive data from the Phase 2 portion of Study 1...
Source: GlobeNewswire
Date: June, 25 2018 07:00
BeyondSpring, Inc. (BYSI) CEO Dr. Lan Huang on Q1 2018 Results - Earnings Call Transcript
BeyondSpring, Inc. (BYSI) Q1 2018 Results Earnings Conference Call June 21, 2018 08:00 AM ET Executives Joe Rayne - Argot Partners Dr. Lan Huang - Co-Founder, Chairman and CEO Edward Liu - CFO Dr. Ramon Mohanlal - Chief Medical Officer Analysts Caroline Palomeque - Maxim ...
Source: SeekingAlpha
Date: June, 21 2018 14:26
BeyondSpring Provides Operational Updates and First-Quarter 2018 Financial Results
NEW YORK, June 21, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the Company) (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced its financial results for the quarter ended March 31, 2018, and prov...
Source: GlobeNewswire
Date: June, 21 2018 07:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0821.4522.0022.439921.455,280
2018-05-1730.0027.6130.0027.4018,791

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-074081,08837.5000Short
2018-12-063,6246,30057.5238Short
2018-12-041,0001,45068.9655Short
2018-12-0365077084.4156Short
2018-11-301,1001,80061.1111Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BYSI.


About BeyondSpring Inc. (NASDAQ: BYSI)

Logo for BeyondSpring Inc. (NASDAQ: BYSI)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $623,875,138 - 05/14/2018
  • Issue and Outstanding: 22,530,702 - 12/31/2017

 


Recent Filings from (NASDAQ: BYSI)

Amendment to a previously filed 20-F
Filing Type: 20-F/AFiling Source: edgar
Filing Date: May, 16 2018
Registration statement for certain foreign private issuers offered for certain transactions
Filing Type: F-3Filing Source: edgar
Filing Date: April, 25 2018
Annual and transition report of foreign private issuers under sections 13 or 15(d)
Filing Type: 20-FFiling Source: edgar
Filing Date: April, 03 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: March, 27 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: February, 21 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 14 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 14 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 14 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: January, 29 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: January, 10 2018

 

 


Daily Technical Chart for (NASDAQ: BYSI)

Daily Technical Chart for (NASDAQ: BYSI)


Stay tuned for daily updates and more on (NASDAQ: BYSI)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: BYSI)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BYSI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of BYSI and does not buy, sell, or trade any shares of BYSI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/